4//SEC Filing
Perlich Irene 4
Accession 0001209191-23-054734
CIK 0001426332other
Filed
Nov 7, 7:00 PM ET
Accepted
Nov 8, 6:11 PM ET
Size
17.4 KB
Accession
0001209191-23-054734
Insider Transaction Report
Form 4
Perlich Irene
Principal Accounting Officer
Transactions
- Award
Stock Option (Right to Buy)
2023-11-06+50,000→ 50,000 totalExercise: $0.84Exp: 2031-03-31→ Common Stock (50,000 underlying) - Disposition to Issuer
Stock Option (Right to Buy)
2023-11-06−17,500→ 0 totalExercise: $5.36Exp: 2032-11-03→ Common Stock (17,500 underlying) - Award
Stock Option (Right to Buy)
2023-11-06+17,500→ 17,500 totalExercise: $0.84Exp: 2032-11-03→ Common Stock (17,500 underlying) - Award
Stock Option (Right to Buy)
2023-11-06+35,000→ 35,000 totalExercise: $0.84Exp: 2032-03-02→ Common Stock (35,000 underlying) - Disposition to Issuer
Stock Option (Right to Buy)
2023-11-06−35,000→ 0 totalExercise: $15.20Exp: 2032-03-02→ Common Stock (35,000 underlying) - Disposition to Issuer
Stock Option (Right to Buy)
2023-11-06−50,000→ 0 totalExercise: $29.62Exp: 2031-03-31→ Common Stock (50,000 underlying)
Footnotes (4)
- [F1]The shares subject to the stock option shall vest over a four-year period commencing March 22, 2021, with 1/4th of the shares vesting on March 22, 2022 and 1/48th of the shares vesting monthly thereafter.
- [F2]Effective November 6, 2023, the Compensation Committee of the Board of Directors of NGM Biopharmaceuticals, Inc. (the "Company") approved a stock option repricing which resulted in, for purposes of Section 16 of the Exchange Act, the cancellation of a previously-granted stock option in exchange for a new stock option having a lower exercise price of $0.84 per share, which is the closing price of the Company's common stock on November 6, 2023. The reduced exercise price is subject to the relevant retention period and other terms outlined in the applicable stock option repricing notice. All of the other terms of the stock option remained unchanged.
- [F3]The shares subject to the stock option vest over a four-year period commencing January 1, 2022, with 1/48th of the shares vesting on a monthly basis.
- [F4]The shares subject to the stock option vest over a two-year period commencing November 4, 2022, with 1/2 of the shares vesting on an annual basis.
Documents
Issuer
NGM BIOPHARMACEUTICALS INC
CIK 0001426332
Entity typeother
Related Parties
1- filerCIK 0001989954
Filing Metadata
- Form type
- 4
- Filed
- Nov 7, 7:00 PM ET
- Accepted
- Nov 8, 6:11 PM ET
- Size
- 17.4 KB